il13r alpha peptide

Peptideexperimental

Clinical trial activity

9 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 1999 (NCT01989572)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • il13r alpha peptide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02754362Phase 2Jul 1, 2017Icahn School of Medicine at Mount Sinai, New York University
NCT02802943Phase 2Oct 1, 2016University of Tuebingen
NCT02600949Phase 1May 1, 2016University of Texas at Houston
NCT00471471Phase 1Oct 1, 2008National Cancer Institute (NCI), University of Pittsburgh
NCT00694551N/AOct 1, 2008National Institutes of Health (NIH), University of South Florida
NCT00845611Phase 1Sep 1, 2008Kindai University, University of Tokyo
NCT02429440Phase 1/Phase 2 (Phase 2)May 1, 2005University of Tuebingen
NCT02452307Phase 1/Phase 2 (Phase 2)Apr 1, 2004University of Tuebingen
NCT01989572Phase 3Dec 1, 1999Emory University, National Cancer Institute (NCI)
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of TuebingenAcademic/Hospital3312004
National Cancer Institute (NCI)Government2121999
Emory UniversityAcademic/Hospital1011999
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012017
Kindai UniversityAcademic/Hospital1112008
National Institutes of Health (NIH)Government1012008
New York UniversityAcademic/Hospital1112017
University of PittsburghAcademic/Hospital1112008
University of South FloridaAcademic/Hospital1112008
University of Texas at HoustonAcademic/Hospital1112016
University of TokyoAcademic/Hospital1012008
11 organizations
Page 1 / 1